By Associate Professor Jane Ellen Carland

Journal articles

Lea-Henry TN; Carland JE; Stocker SL; Sevastos J; Roberts DM, 2018, 'Clinical pharmacokinetics in kidney disease: Fundamental principles', Clinical Journal of the American Society of Nephrology, 13, pp. 1085 - 1095, http://dx.doi.org/10.2215/CJN.00340118

Nguyen AD; Frensham LJ; Baysari MT; Carland JE; Day RO, 2018, 'Patients' use of mobile health applications: What general practitioners think', Family Practice, 36, pp. 214 - 218, http://dx.doi.org/10.1093/fampra/cmy052

Carland JE; Thomas M; Mostyn SN; Subramanian N; O'Mara ML; Ryan RM; Vandenberg RJ, 2018, 'Molecular Determinants for Substrate Interactions with the Glycine Transporter GlyT2', ACS Chemical Neuroscience, 9, pp. 603 - 614, http://dx.doi.org/10.1021/acschemneuro.7b00407

Day R; Kamel B; Graham GG; Williams KM; Stocker SL; Carland JE; Pile KD; Mcguigan LE; Portek IJ; Mcgill NW, 2018, 'A Multicentre Open-Label Pharmacokinetic-Pharmacodynamic Study of Febuxostat in Patients with Chronic Gout', Proceedings for Annual Meeting of The Japanese Pharmacological Society, WCP2018, http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_po1-11-12

Mostyn SN; Carland JE; Shimmon S; Ryan RM; Rawling T; Vandenberg RJ, 2017, 'Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2', ACS Chemical Neuroscience, 8, pp. 1949 - 1959, http://dx.doi.org/10.1021/acschemneuro.7b00105

Day RO; Kannangara DRW; Stocker SL; Carland JE; Williams KM; Graham GG, 2017, 'Allopurinol: insights from studies of dose–response relationships', Expert Opinion on Drug Metabolism and Toxicology, 13, pp. 449 - 462, http://dx.doi.org/10.1080/17425255.2017.1269745

Vandenberg RJ; Mostyn SN; Carland JE; Ryan RM, 2016, 'Glycine transporter2 inhibitors: Getting the balance right', Neurochemistry International, 98, pp. 89 - 93, http://dx.doi.org/10.1016/j.neuint.2015.12.007

Subramanian N; Scopelliti AJ; Carland JE; Ryan RM; O'Mara ML; Vandenberg RJ, 2016, 'Correction: Identification of a 3^rd Na⁺ binding site of the glycine transporter, GlyT2', PLoS ONE, 11, http://dx.doi.org/10.1371/journal.pone.0159896

Subramanian N; Scopelitti AJ; Carland JE; Ryan RM; O'Mara ML; Vandenberg RJ, 2016, 'Identification of a 3^rd Na⁺ binding site of the glycine transporter, GlyT2', PLoS ONE, 11, pp. e0157583, http://dx.doi.org/10.1371/journal.pone.0157583

Vandenberg R; Carland J; Edington A; Ryan R, 2015, 'Molecular Basis for Substrate and Inhibitor Interactions with the Glycine Transporter, GlyT2', FASEB JOURNAL, 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361470504039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carland JE; Yamamoto I; Hanrahan JR; Abdel-Halim H; Lewis TM; Absalom N; Chebib M, 2015, 'A Hydrophobic Area of the GABA ρ1 Receptor Containing Phenylalanine 124 Influences Both Receptor Activation and Deactivation', Journal of Molecular Neuroscience, 55, pp. 305 - 313, http://dx.doi.org/10.1007/s12031-014-0322-7

Vandenberg RJ; Ryan RM; Carland JE; Imlach WL; Christie MJ, 2014, 'Glycine transport inhibitors for the treatment of pain', Trends in Pharmacological Sciences, 35, pp. 423 - 430, http://dx.doi.org/10.1016/j.tips.2014.05.006

Carland JE; Handford CA; Ryan RM; Vandenberg RJ, 2014, 'Lipid inhibitors of high affinity glycine transporters: Identification of a novel class of analgesics', Neurochemistry International, 73, pp. 211 - 216, http://dx.doi.org/10.1016/j.neuint.2013.08.012

Carland JE; Cooper MA; Livesey MR; Hales TG; Peters JA; Lambert JJ, 2013, 'Mutagenic analysis of the intracellular portals of the human 5-HT 3A receptor', Journal of Biological Chemistry, 288, pp. 31592 - 31601, http://dx.doi.org/10.1074/jbc.M113.503300

Carland JE; Mansfield RE; Ryan RM; Vandenberg RJ, 2013, 'Oleoyl-L-carnitine inhibits glycine transport by GlyT2', British Journal of Pharmacology, 168, pp. 891 - 902, http://dx.doi.org/10.1111/j.1476-5381.2012.02213.x

Yamamoto I; Absalom N; Carland JE; Doddareddy MR; Gavande N; Johnston GAR; Hanrahan JR; Chebib M, 2012, 'Differentiating enantioselective actions of GABOB: A possible role for threonine 244 in the binding site of GABAc ρ1 receptors', ACS Chemical Neuroscience, 3, pp. 665 - 673, http://dx.doi.org/10.1021/cn3000229

Yamamoto I; Carland JE; Locock K; Gavande N; Absalom N; Hanrahan JR; Allan RD; Johnston GAR; Chebib M, 2012, 'Structurally diverse GABA antagonists interact differently with open and closed conformational states of the ρ1 receptor', ACS Chemical Neuroscience, 3, pp. 293 - 301, http://dx.doi.org/10.1021/cn200121r

Peters JA; Cooper MA; Carland JE; Livesey MR; Hales TG; Lambert JJ, 2010, 'Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors', Journal of Physiology, 588, pp. 587 - 596, http://dx.doi.org/10.1113/jphysiol.2009.183137

Sugiharto S; Carland JE; Lewis TM; Moorhouse AJ; Barry PH, 2010, 'External divalent cations increase anion-cation permeability ratio in glycine receptor channels', Pflugers Archiv - European Journal of Physiology, 460, pp. 131 - 152, http://dx.doi.org/10.1007/s00424-010-0792-6

Carland JE; cooper MA; Sugiharto S; Jeong H; Lewis TM; Barry PH; Peters JA; Lambert J; Moorhouse AJ, 2009, 'Characterization of the effects of charged residues in the intracellular loop on ion permeation in α1 glycine receptor channels', The Journal of Biological Chemistry, 284, pp. 2023 - 2030, http://dx.doi.org/10.1074/jbc.M806618200

Carland JE; Johnston G; Chebib M, 2008, 'Relative impact of residues at the intracellular and extracellular ends of the human GABA(C) rho 1 receptor M2 domain on picrotoxinin activity', European Journal of Pharmacology, 580, pp. 27 - 35

Livesey M; Cooper M; Deeb T; Carland JE; kozuska J; Hales T; Lambert J; Peters J, 2008, 'Structural determinants of Ca2+ permeability and conduction in the human 5-hydroxytryptamine type 3A receptor', The Journal of Biological Chemistry, 283, pp. 19301 - 19313

Deeb T; Carland JE; Cooper MA; Livesey M; Lambert J; Peters J; Hales T, 2007, 'Dynamic modification of a mutant cytoplasmic residue modulates the conductance of the human 5-HT3A receptor', The Journal of Biological Chemistry, 282, pp. 6172 - 6182, http://dx.doi.org/10.1074/jbc.M607698200

Hales T; Dunlop JI; Deeb T; Carland JE; Kelley SP; Lambert J; Peters J, 2006, 'Common determinants of single channel conductance within the large cytoplasmic loop of 5-HT3 and á4â2 nicotinic acetylcholine receptors', The Journal of Biological Chemistry, 281, pp. 8062 - 8071, http://dx.doi.org/10.1074/jbc.M513222200

Peters J; Carland JE; Cooper MA; Livesey M; Deeb T; Hales T; Lambert J, 2006, 'Novel structural determinants of single channel conductance in nicotinic acetylcholine and 5-hydroxytryptamine type-3 receptors', Biochemical Society Transactions, 34, pp. 882 - 886, http://www.biochemsoctrans.org/bst/034/0882/0340882.pdf

Barker D; Lin DH-S; Carland JE; Chu CP-Y; Chebib M; Brimble MA; Savage GP; McLeod MD, 2005, 'Methyllycaconitine analogues have mixed antagonist effects at nicotinic acetylcholine receptors', Bioorganic and Medicinal Chemistry, 13, pp. 4565 - 4575, http://dx.doi.org/10.1016/j.bmc.2005.04.054

Carland JE; Moorhouse AJ; Barry PH; Johnston G; Chebib M, 2004, 'Charged residues at the 2 ` position of human GABA(c) rho 1 receptorsinvert ion selectivity and influence open state probability', The Journal of Biological Chemistry, 279, pp. 54153 - 54160

Carland JE; Moore AM; Hanrahan JR; Mewett KN; Duke RK; Johnston G; Chebib M, 2004, 'Mutations of the 2' proline in the M2 domain of the human GABAC ĉ1 subunit alter agonist responses', Neuropharmacology, 46, pp. 770 - 781, http://dx.doi.org/10.1016/j.neuropharm.2003.11.027

Back to profile page